Systemic-onset juvenile idiopathic arthritis: Difference between revisions
CSV import |
CSV import |
||
| Line 77: | Line 77: | ||
[[Category:Rare diseases]] | [[Category:Rare diseases]] | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
<gallery> | |||
File:Diseases_of_children_(1916)_(14579765477).jpg | |||
</gallery> | |||
Revision as of 02:02, 17 February 2025
| Systemic-onset juvenile idiopathic arthritis | |
|---|---|
| [[File:|250px|alt=|]] | |
| Synonyms | Systemic juvenile idiopathic arthritis |
| Pronounce | |
| Field | pediatrics/rheumatology |
| Symptoms | |
| Complications | |
| Onset | |
| Duration | |
| Types | |
| Causes | |
| Risks | |
| Diagnosis | |
| Differential diagnosis | |
| Prevention | |
| Treatment | |
| Medication | |
| Prognosis | |
| Frequency | |
| Deaths | |
Systemic-onset juvenile idiopathic arthritis or the juvenile onset form of Still's disease<ref>
Still's Disease(link). MedicineNet.
</ref>) is a type of juvenile idiopathic arthritis (JIA) with extra-articular manifestations like fever and rash apart from arthritis. It was originally called systemic-onset juvenile rheumatoid arthritis or Still's disease.
Predominantly extra-articular manifestations like high fevers, rheumatic rash, enlargement of the liver and spleen, enlargement of the lymph nodes, and anemia. Others manifestations include inflammation of the pleura, inflammation of the pericardium, inflammation of the heart's muscular tissue, and inflammation of the peritoneum are also seen. (April 2014)
It is sometimes called "juvenile-onset Still's disease", to distinguish it from adult-onset Still's disease. However, there is some evidence that the two conditions are closely related.<ref name="pmid12102485">,
"Adolescent-onset Still's disease": characteristics and outcome in comparison with adult-onset Still's disease, Clin. Exp. Rheumatol., 2002, Vol. 20(Issue: 3), pp. 427–30, PMID: 12102485,</ref>
Presentation
Systemic JIA is characterized by arthritis, fever, which typically is higher than the low-grade fever associated with polyarticular and a salmon pink rash. It accounts for 10-20% of JIA and affects males and females equally, unlike the other two subtypes of JIA, and affects adolescents. It generally involves both large and small joints. Systemic JIA can be challenging to diagnose because the fever and rash come and go. Fever can occur at the same time every day or twice a day (often in late afternoon or evening) with a spontaneous rapid return to baseline (vs. septic arthritis of continuous fever). The rash often occurs with fever. It is a discrete, salmon-pink macules of different sizes. It migrates to different locations on skin, rarely persisting in one location more than one hour. The rash is commonly seen on trunk and proximal extremities or over pressure areas.
Arthritis is often absent in the first weeks or even 6–8 months into the illness.
Systemic JIA may have internal organ involvement such as hepatosplenomegaly, lymphadenopathy, serositis, hepatitis, or tenosynovitis. (April 2014)
A polymorphism in macrophage migration inhibitory factor has been associated with this condition.<ref name="pmid12746913">,
Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis, Arthritis Rheum., Vol. 48(Issue: 5), pp. 1398–407, DOI: 10.1002/art.10882, PMID: 12746913,</ref>
Cause
The cause is unknown but it's thought to be related to environmental, genetic, and hormonal factors.
Diagnosis
Rheumatoid factor and ANA tests are generally negative in systemic JIA. Lab findings: anemia of chronic disease, neutrophilia, thrombocytosis, elevated acute phase reactants (ESR, CRP, ferritin).
Treatment
Treatment with either glucocorticoids, methotrexate, anakinra, or tocilizumab has been examined.<ref name="pmid22290637">,
Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis, Arthritis Care & Research, Vol. 64(Issue: 7), pp. 1001–10, DOI: 10.1002/acr.21625, PMID: 22290637, PMC: 3368104,</ref> Anakinra has been shown to resolve the clinical features of the disease in 87% of patients.<ref name="Vastert2012">, IL-1 receptor antagonist restores IL-18 NK cell axis in systemic JIA, Journal of Translational Medicine, Vol. 10(Issue: Suppl 3), pp. P45, DOI: 10.1186/1479-5876-10-S3-P45, PMC: 3508836,</ref> It also induces remission in half of corticosteroid-resistant patients.<ref name="Wulffraat2008">, Early effects of Anakinra in corticosteroid naïve SOJIA patients, Pediatric Rheumatology, Vol. 6(Issue: Suppl 1), pp. P29, DOI: 10.1186/1546-0096-6-S1-P29, PMC: 3334087,</ref> The results of another study were similar, with half of the patients responding to treatment with Anakinra.<ref name="pmid18438814">, The pattern of response to anti–interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis, Arthritis & Rheumatism, Vol. 58(Issue: 5), pp. 1505–1515, DOI: 10.1002/art.23437, PMID: 18438814,</ref> Canakinumab, an antibody to
interleukin-1 beta, is indicated for treatment in patients who respond poorly to other treatments.<ref>http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001109/WC500031680.pdf</ref>
Prognosis
25% of cases progress to severe destructive arthritis.<ref name="pmid16645998">Singh-Grewal, D.,
Predictors of disease course and remission in systemic juvenile idiopathic arthritis: Significance of early clinical and laboratory features, Arthritis & Rheumatism, Vol. 54(Issue: 5), pp. 1595–1601, DOI: 10.1002/art.21774, PMID: 16645998,</ref> In the United States, mortality is estimated at about 4% <ref>Hoffman, F., Background Information, Roche Group Media Relations, http://www.roche.com/med-ra-sjia.pdf.pdf</ref> and in Europe, mortality is estimated at 21.7%.<ref>Davies, Rebecca, Standardized Mortality Rates are Increased in Patients with Severe Juvenile Idiopathic Arthritis, Oxford Journal of Rheumatology, Vol. 54(Issue: 1), pp. i153, Full text,</ref>
History
Still's disease is named after English physician Sir George Frederic Still (1861–1941).<ref>synd/1773 at Who Named It?</ref><ref>G. F. Still. A special form of joint disease met with in children. Doctoral dissertation, Cambridge, 1896.</ref> It was characterized by EG Bywaters in 1971.<ref name="pmid5315135">Bywaters EG,
Still's disease in the adult, Ann. Rheum. Dis., Vol. 30(Issue: 2), pp. 121–33, DOI: 10.1136/ard.30.2.121, PMID: 5315135, PMC: 1005739, Full text,</ref><ref name="pmid22573189">Cimaz, R, Systemic-onset juvenile idiopathic arthritis: the changing life of a rare disease, Swiss Medical Weekly, Vol. 142, pp. w13582, DOI: 10.4414/smw.2012.13582, PMID: 22573189, Full text,</ref>
References
<references group="" responsive="1"></references>
